Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 3,280	$ 1,820	$ 7,352	$ 8,495
Research and development
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	1,219	144	3,126	2,951
General and administrative
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 2,061	$ 1,676	$ 4,226	$ 5,544